Summary. Medical radionuclide production technology is well established. Both reactors and cyclotrons are utilized for production; the positron emitters, however, are produced exclusively using cyclotrons. A brief survey of the production methods of most commonly used diagnostic and therapeutic radionuclides is given. The emerging radionuclides are considered in more detail. They comprise novel positron emitters and therapeutic radionuclides emitting low-range electrons and α-particles. The possible alternative production routes of a few established radionuclides, like 68 Ga and 99m Tc, are discussed. The status of standardisation of production data of the commonly used as well as of some emerging radionuclides is briefly mentioned. Some notions on anticipated future trends in the production and application of radionuclides are considered.
Introduction
Radioactivity is unique in the sense that, in spite of its hazardous nature, it finds application in medicine both in diagnosis and therapy [cf . 1] . Each application, however, demands a special type of radionuclide. For in vivo diagnostic investigations involving organ imaging, for example, radionuclides are required that can be efficiently detected from outside of the body. To this end, short-lived γ -ray emitters, like 99m Tc and 123 I, and positron emitters, like 11 C and 18 F, are commonly used, the former finding application in Single Photon Emission Computed Tomography (SPECT) and the latter in Positron Emission Tomography (PET). The underlying principle in diagnostic nuclear medicine is that the radiation dose to the patient is as low as possible, compatible with the required quality of imaging and the diagnostic advantage in comparison to non-radioactive methods. Thus a complete set of decay data of a radionuclide is required to be able to calculate the radiation dose which plays a very important role in its choice for a diagnostic medical application.
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The therapeutic application of radioactivity involves either external radiation therapy or internal radiotherapy. Whereas for the former, radionuclides emitting energetic β − particles or hard γ -rays are commonly used, for example 60 Co (T 1/2 = 5.27 a), 137 Cs (T 1/2 = 30.17 a) and 192 Ir (T 1/2 = 73.8 d), the spectrum of radionuclides required in internal radionuclide therapy (endotherapy) is very broad. Since in this case a localised, well-defined radiation dose needs to be deposited in a malignant or inflammatory tissue, radionuclides emitting low-range highly-ionising radiation, i.e. α or β − particles, conversion and/or Auger electrons, are of great interest.
The medical radionuclide production technology is well developed and is pursued both at commercial centres and some nuclear science research institutes. However, besides routine production and medical application of radionuclides, constant research work is going on around the world to improve the existing production methodologies of some established radionuclides as well as to develop novel radionuclides for new medical applications. Some thoughts and efforts are also constantly devoted to future development of this technology to meet the challenges of new approaches in medical investigations.
The production of radionuclides is carried out using nuclear reactors [for reviews cf . 2, 3] and accelerators/cyclotrons [for a review cf . 4]. The reactor production generally leads to neutron excess radionuclides. They mostly decay by β − emission and are therefore especially suitable for radiotherapy. The cyclotron produced radionuclides, on the other hand, are mainly neutron deficient and decay by electron capture (EC) or β + emission. They are therefore particularly useful for diagnostic studies. The positron emitters can be produced only at cyclotrons. For production of some nuclides both nuclear reactors and cyclotrons are extensively used. In other words, their roles are to be regarded as complementary. Worldwide there exist about 400 research reactors and about 500 cyclotrons. Most of them are at least partly used for production of medically useful radionuclides. The radionuclide production technology today has thus become an integral part of modern nuclear medicine and its future prospects also appear to be bright.
This article deals with three aspects of medical radionuclide production technology. In the first part, the routine production for state-of-the-art patient care is briefly outlined; in the second, the on-going new developments are discussed in some detail; and in the third, some emerging thoughts relevant to the future perspectives of this technology are considered.
Present status of radionuclide production technology
The radionuclides commonly used in medicine and in drug development are listed in Table 1 , together with their decay properties and production routes [cf . 1, 5] . They are divided in four groups depending on the function they serve. Each group is discussed below.
Soft β − emitters for in vitro studies
In this group the most important radionuclides include 3 H (T 1/2 = 12.3 a), 14 C (T 1/2 = 5730 a) and 125 I (T 1/2 = 59.4 d). They are available in large quantities in all parts of the world. Over the last 60 years, the radionuclides 3 H and 14 C have played a very important role in biochemistry for enhancing our understanding of physiological functions of molecules and radiopharmaceuticals (drug development research). This was possible due to the relatively simple method of measurement of their radioactivity via liquid scintillation counting. The radionuclide 125 I with its low-energy emissions is very well suited for autoradiography and is commonly used in radioimmunoassay or receptor binding studies.
All the three radionuclides mentioned above are produced in a nuclear reactor: Tritium via the 6 Li(n, α)-reaction on a Li or LiF target, 14 C through the 14 N(n, p)-reaction on an AlN target, and 125 I using the 124 Xe(n, γ ) 125 Xe → 125 I process by irradiating nat Xe or enriched 124 Xe filled in an Al-capsule. Tritium is generally available as tritium gas or tritiated water, 14 C as 14 CO 2 or Ba 14 CO 3 , and 125 I as 125 I − . In addition to the three major soft β − emitting radionuclides mentioned above, two other soft β − emitting nuclides, namely 33 P (T 1/2 = 25.3 d; E β − = 248 keV) and 35 S (T 1/2 = 87.5 d; E β − = 167 keV), also find some limited application involving in vitro investigations. Both are produced in the no-carrier-added form in a high fast flux nuclear reactor, the former via the 33 S(n, p) 33 P reaction on isotopically enriched 33 S and the latter through the 35 Cl(n, p) 35 S reaction on a KCl target [cf . 6] . The radionuclides 33 P and 35 S are generally available as H 3 33 PO 4 and H 2 35 SO 4 , respectively, besides other forms.
Gamma emitters for SPECT
The number of γ -ray emitters which have found some application in imaging using gamma cameras is relatively large. However, with the advent of SPECT tomographs, it became incumbent to use radionuclides emitting either only one γ -ray or at least one predominant γ -ray within the energy range of 100-200 keV. The choice was thus reduced to five radionuclides, namely 67 Ga (T 1/2 = 3.26 d), 99m Tc (T 1/2 = 6.0 h), 111 In (T 1/2 = 2.8 d), 123 I (T 1/2 = 13.2 h) and 201 Tl (T 1/2 = 3.06 d). The radionuclide 99m Tc is by far the most commonly used SPECT radionuclide. It ideally emits a 141 keV photon and causes the least radiation dose to the patient. It is almost always available in a clinic via the 99 Mo/ 99m Tc generator system. Furthermore, by virtue of its versatile complex formation chemistry, labelling methods are established to rather easily bind it to various compounds. This characteristic has led to development of several robust labelling kits. The eluted 99m Tc as pertechnetate is transferred to an ampoule containing an appropriate lyophilised mixture of reagents. On shaking, the labelling of given ligands with 99m Tc occurs in a specific configuration and the product is then ready for human use. Also the radionuclide 123 I is commonly used. However, due to its lesser availability and higher cost, 123 I is much less broadly used than 99m Tc. The third radionuclide, viz.
201 Tl, is extensively used for myocardial perfusion measurements. The remaining two radionuclides, namely 67 Ga and 111 In are less commonly used as SPECT agents. They are partly being considered for therapeutic applications because they emit a large number of Auger electrons.
As mentioned above, 99m Tc is available via the 99 Mo/ 99m Tc generator. An Al 2 O 3 -column is loaded with 99 Mo and the daughter activity is periodically removed by elution with saline. The parent nuclide 99 Mo (T 1/2 = 66.0 h) is produced at a nuclear reactor, and two routes are possible: 98 Mo(n, γ ) 99 Mo and 235 U(n, f ) 99 Mo. The cross section of the (n, γ )-reaction is relatively small and due to the use of nat Mo (with a 98 Mo content of 24.13%) as target material, the specific activity of the 99 Mo produced is low. Thus, because of the heavy loading of the Al 2 O 3 -generator column with stable molybdenum, in spite of the rather big dimensions of the column, the risk of breakthrough of Mo is high and 99m Tc eluate volumes are large. Somewhat higher specific activity is achieved using a high-flux nuclear reactor. However, such reactors are seldom available for radionuclide production. Attempts have been made to enrich 99 Mo via a Szilard Chalmers process [cf . 7] but the separation yields are low. Furthermore, some gel and distillation generators have been developed [cf . 8, 9] but their overall efficiencies are not comparable to that of the alumina column generator. In view of the situation, combined with the fact that for production purposes irradiations are mostly done at medium-flux reactors, the method of choice for production of 99 Mo for medical use is the fission process.
The cross section for the thermal neutron induced fission of 235 U is 596 barn and the cumulative yield of 99 Mo is 6.16%; thus TBq amounts of 99 Mo can be produced per batch. Although the chemical processing of the irradiated target is very laborious, especially in view of the high demand on the quality assurance of the separated product, only the fission process is accepted because it leads to 99 Mo of very high specific activity. In fact the fission produced 99 Mo on an Al 2 O 3 column is regarded as a gold standard generator system. The eluted 99m Tc occurs as pertechnetate. The ease and success associated with the generator elution of 99m Tc and the development of kit formulation of some very important 99m Tc-labelled diagnostic agents has led to the very wide use of 99m Tc. The fission 99 Mo is produced only at a few advanced centres and is then distributed to various laboratories around the world where the generator loading is undertaken (dispensing). The generators are then sent to regional clinics. It is estimated that worldwide 35 million patients per year are subjected to diagnostic investigations with 99m Tc [cf . 10] . Despite this success story and the demonstrated need for continuous availability of this radionuclide, its future supply appears to be somewhat 121 Te (T 1/2 = 154 d) which is a disadvantage. An energy control of the beam incident on the target is therefore mandatory. The activated xenon gas is allowed to decay for about 7 h and 123 I is then collected by rinsing the inner wall of the container. This method of production is now commonly used because it gives the purest product and is the only one accepted by regulations in most countries. The enriched target gas 124 Xe is relatively expensive. The technology related to irradiation and safe recovery of the target gas as well as an efficient removal of 123 I from the target wall is thus very demanding. This technology is, however, now commercially available.
The third method of production of 123 I utilizes the intermediate energy nuclear process 127 I( p, 5n) 123 Xe → 123 I, the optimum energy range being E p = 65 → 45 MeV. The product 123 Xe is removed from the NaI target, collected in a vessel and is allowed to decay for about 7 h. Thereafter 123 I is collected in a small volume by rinsing the inner wall of the vessel. This process leads to a high yield of 123 The above mentioned two less commonly used SPECT radionuclides, namely 67 Ga and 111 In, which are now also considered for Auger therapy (see below) are produced at a medium-sized cyclotron over the optimum energy range of E p = 25 → 18 MeV via the nuclear reactions 68 Zn( p, 2n) 67 Ga and 112 Cd( p, 2n) 111 In, respectively [cf . 4]. In each case an enriched target is used and efficient methods of chemical purification have been worked out. The two radionuclides are commercially available in GBq amounts.
Positron emitters for PET
The number of positron-emitting radionuclides is large. For present day medical diagnostic imaging, the radionuclide used should have a short half-life, and emit only a low energy positron and possibly no high-energy γ -ray. Thus for routine PET investigations, mainly the short-lived organic positron emitters, viz.
11 C (T 1/2 = 20.4 min) and 18 F (T 1/2 = 110 min), and to a lesser extent 15 O (T 1/2 = 2 min) and 13 N (T 1/2 = 10 min), are used. The radionuclides 11 C, 13 N and 15 O are generally used at the site of production. 18 F, on the other hand, is extensively employed for transport to nearby medical units having a PET but not a cyclotron. They can all be produced at low-energy cyclotrons. Besides those four positron emitters, two other short-lived positron emitters, namely 68 15 O, in a few PET centres a small single particle cyclotron (E d < 4 MeV) has also been successfully utilized.
Regarding the technical aspects of production of shortlived positron emitters, considerable attention has been devoted over the last 25 years to high-current targetry and chemical processing. For production of 11 C and 15 O, for example, high-pressure gas targets have been developed, and the two radionuclides can be easily obtained in 100 GBq quantities. The chemical form of the product coming out of the target depends on the composition of the target gas and the accumulated radiation dose. Thus precursors for labelling work with 11 18 F can now be produced in quantities up to 100 GBq per target batch.
As mentioned above, the production of the parent nuclides of the two commonly used generator-produced β + emitters, namely 68 Ga and 82 Rb, is done using intermediate energy reactions [cf . 15] . The radionuclide 68 Ge is basically produced via the 69 Ga( p, 2n) 68 Ge reaction since the cross section is rather high (see discussion below). However, due to its long half-life, the yield is low and high proton beam fluxes approaching the mA level are essential. Furthermore, long irradiations are required. It is partly obtained via the spallation of bromine or arsenic; however, the purification of the product is cumbersome. Due to the increasing significance of the β + emitter 68 Ga (see discussion below), more concerted efforts are needed to ensure its continuous supply. The radionuclide 82 Sr is produced today mainly via the nat Rb( p, xn)-process at E p = 70 → 50 MeV. A consortium of laboratories collaborates in irradiations but the chemical processing is mainly done at Los Alamos. The purified 82 Sr is then distributed worldwide to prepare generators. Recently the available generator has come to some disrepute because of the breakthrough of the long-lived radiostrontium. Efforts to remediate this drawback are underway.
In recent years, PET imaging has been gaining enhanced significance because it leads to quantitative information on regional physiological and pharmacological activities by a molecular probe (labelled with a positron emitter) with high sensitivity and with a spatial resolution down to 1 mm. The major impetus came through the production of 18 F in large quantities via the 18 O( p, n) 18 F reaction [13, 16 ] at a small cyclotron followed by a simplified method of nucleophilic substitution by 18 F in organic molecules [17] . This led in particular to the preparation of the most frequently used PET-tracer 2-[
18 F]-fluoro-2-desoxy-D-glucose in large amounts [18] . This radiopharmaceutical is now extensively used in neurology, cardiology and oncology. It is estimated that worldwide a few million patients per year are treated using this radiopharmaceutical. Today, the whole PET technology (consisting of cyclotron, radionuclide production unit, and automated radiosynthesis apparatus) is commercially available. It is now reaching almost all corners of the globe.
Radionuclides for internal radiotherapy
As mentioned above, for internal radiotherapy β − , α-, Auger electron and X-ray emitters are of great interest [cf . 1, 19] . In the simplest case the radiation emitter is brought mechanically to the vicinity of the tumour to be treated. This type of therapy, known as brachytherapy, is commonly performed with 192 Ir (T 1/2 = 73.8 d) in the form of a wire, 125 I (T 1/2 = 59.4 d) as a stent or 103 Pd (T 1/2 = 17.0 d) as a seed or a stent. In the case of 192 Ir, the long-range β − particles are effective but in the latter two cases, X-rays cause the therapeutic effect. After a given period the radioactive source is removed from the organ. A more common application is palliative therapy. Radionuclides like 32 P (T 1/2 = 14.3 d) and 90 Y (T 1/2 = 2.7 d), which are pure β − emitters with rather high β − energy, are introduced into joints and cavities as gels, glass microspheres or conglomerates. In case of small joints, 169 Er (T 1/2 = 9.4 d) with low β − energy, is also used. Great care needs to be taken of the size of the particulate matter so that it does not ooze out of the cavity. The interaction of the radiation with the membrane covering the inner surface of the bone leads to palliative effect. A third variation of internal radiotherapy with β − emitters involves the radiosynthesis of tumour seeking agents. For this purpose the radionuclides 89 Regarding the α-emitters, to date many preclinical and some clinical studies have been performed using 211 At (T 1/2 = 7.2 h). In fact the application of 211 At has a very long story, but it is still in the research phase. The radionuclide 225 Ac is potentially very important but it is still under development and is therefore treated in the next section. As far as Auger electron therapy is concerned, to date most of the experimental studies have been performed using 125 I. The low range of the Auger electrons demands that the radiopharmaceutical, e.g. a labelled DNA compound, has the chance of reaching the cell nucleus in order to destroy the tumour. Thus 125 I finds great interest not only for in vitro applications (see above) but is attractive for internal radiotherapy of tumours as well.
The production of the therapeutic radionuclides 32 P and 89 Sr with high specific activity is carried out in a nuclear reactor via the 32 S(n, p) 32 P and 89 Y(n, p) 89 Sr reactions, respectively. The cross sections are rather low and therefore the yields are also low. Large amounts of 89 Sr, for example, are produced at the high fast flux reactor RIAR in Dimitrovgrad, Russia, based on long irradiations of about 60 days [cf . 6]. The radionuclide 131 I is typically produced via the fission process, but the precursor system 130 Te(n, γ ) 131m,g Te → 131 I, similar to the 124 Xe(n, γ ) 125 Xe → 125 I system described above for 125 I, is also used. Both those radionuclides are thus obtained with high specific activity. For the production of the radionuclides 90 In contrast to the above mentioned seven therapeutic radionuclides (i.e. 32 P, 89 Sr, 90 Y, 125 I, 131 I, 177 Lu and 188 Re) which are produced with high specific activity via irradiations in a nuclear reactor, the yield and the specific activity of the radionuclide 103 Pd, originally produced in a nuclear reactor via the reaction 102 Pd(n, γ ) 103 Pd, could not be improved. The production has therefore shifted from reactor to cyclotron. It is now routinely produced via the 103 Rh( p, n)-reaction, though the 103 Rh(d, 2n)-process is also interesting (for a recent review on nuclear data cf . [21] ). Over the last 15 years about 20 cyclotrons have been installed in USA to produce exclusively 103 Pd, because this radionuclide is commonly used in treatment of prostate cancer, though now with a declining trend.
As far as the radionuclide 153 Sm is concerned, production is done at a reactor via the 152 Sm(n, γ )-reaction. Consequently the specific activity is not high. On the other hand, since the cross section for this reaction is relatively high (206 b), the specific activity of 153 Sm is not as low as in the case of many other radionuclides produced via the (n, γ )-reaction.
Regarding the production of the α-emitting radionuclide 211 At, the only reaction utilized so far is the 209 Bi(α, 2n) 211 At process. A precise control of the energy range is absolutely necessary to avoid the formation of the radioisotope 210 At which decays to long- 
New developments
In recent years, development work related to radionuclide production has been carried out mainly in four directions: -Development of novel positron emitters, -Development of novel highly ionising radiation emitters for internal radiotherapy, -Development of novel methodologies for production of some established radionuclides, -Standardisation of production data. A brief discussion of those areas is given below.
Novel positron emitters
With the growing significance of PET in diagnostic nuclear medicine, the need for novel positron emitters, also termed as non-standard or innovative positron emitters, has been increasing, especially for studying slower metabolic processes and for quantification of targeted therapy [cf . 23, 24] . Those radionuclides, like the commonly used positron emitters, are also produced exclusively at cyclotrons (or accelerators). The subject has been treated in detail in a recent review [25] . In this article, therefore, only some salient features are discussed. Most of the novel positron emitters have been developed at laboratories where facilities for the production of standard positron emitters already existed. Some of the very promising non-standard positron emitters are given in Table 2 . The common route of production of each radionuclide is the lowenergy ( p, n)-reaction on an enriched target isotope. In a few cases other low-energy reactions, such as (d, n) and (p, α), have also been employed. For all those radionuclides some sort of novel medical application has been reported. For a few radionuclides, like 64 Cu, 124 I and 86 Y, a large number of applications have already been demonstrated. The number of relevant reactions studied has therefore also been correspondingly large [cf . 26, 27] . However, the low-energy ( p, n)-reaction on an enriched target isotope is favoured because it generally leads to a high-purity product.
A typical excitation function of the commonly used ( p, n)-reaction for the production of a novel positron emitter in the medium mass range is shown in Fig. 1 . The threshold lies at about 3 MeV and the maximum at about 10 MeV. Thereafter the cross section decreases due to the onset of the competing ( p, 2n)-reaction. The optimum energy range for production is thus between 7 and 14 MeV. This energy region is within the capacity of a small medical cyclotron and therefore (as mentioned above) most of the development work on novel positron emitters has been done at established PET centres. The ( p, n)-reaction can be described relatively well by nuclear model calculations and thus, if many data points are available, a theory-based evaluation is possible [28] . Fig. 1 shows, as an example, the data for the excitation function of the 64 Ni( p, n) 64 Cu reaction (for original references cf . [28] ).
The production of the three more widely used novel positron emitters, viz. 64 Cu, 124 I and 86 Y, mainly developed at the Research Centre Jülich, is described in some detail below.
The radionuclide 64 Cu emits low-energy positrons, has no disturbing γ -ray, has a suitable half-life and forms in- Fig. 1 . Experimental data along with the results of nuclear model calculations using the codes EMPIRE, STAPRE and TALYS for the 64 Ni( p, n) 64 Cu reaction. The encircled data were deselected in further evaluation (taken from Ref. [28] ).
teresting stable co-ordination compounds. It is thus very suitable for studying slow metabolic processes. However, the positron branching is only 17.8% [29] , so that much higher radioactivity has to be injected to achieve a coincidence rate similar to that, for example, with 18 Fradiopharmaceuticals. In addition, the remaining 82.2% decay branching (β − , EC) induces a non-negligible radiation dose. Due to this reason 64 Cu allows a combination of PET with radioimmunotherapy.
The suggested production route 64 Ni( p, n) 64 Cu [30] involves the use of the rather expensive highly enriched target material electroplated on a gold surface. Nonetheless, the technology has been well developed [30] [31] [32] [33] [34] [35] for production of 64 Cu in batches of about 40 GBq and recovery of the enriched target material. The separation of 64 Cu is generally done via anion-exchange chromatography. A recent work [36] describes sophisticated targetry calculations. Due to increasing demand for this radionuclide in radioimmunotherapy, presently a commercialization of this production process is being pursued. However, systematic human use is pending.
In comparison to the 64 Ni( p, n) 64 Cu reaction, for the 64 Ni(d, 2n) 64 Cu reaction only cross section measurements have been reported. Although the expected yield of 64 Cu via the latter reaction is higher, the availability of only lowenergy deuterons at medical cyclotrons has precluded the use of this reaction for production purposes. On the other hand, small amounts of 64 Cu have been produced using a deuteron induced reaction on 64 86 Y involve: (a) coprecipitation with La(OH) 3 followed by ion-exchange separation of radioyttrium from bulk lanthanum [47, 48] , (b) electrolysis [49] [50] [51] , (c) multiple column chromatography [52] , (d) solvent extraction [53] and (e) simple precipitation of the target element [54, 55] . Out of those processes, the electrolytic method appears to be more promising. The radionuclide 86 Y has become the most suitable positron emitter for quantification of radiation dosimetry of 90 Y-labelled therapeuticals. Due to the ever increasing demand for this radionuclide, its large scale production is either already established or is being planned at several centres.
Despite the above discussed capability of low-energy nuclear reactions on enriched target isotopes to produce many novel positron emitters, there are some radionuclides which can be obtained only using intermediate energy reactions (for a detailed discussion cf . [25] 3 He-and α-particles may also induce a few useful reactions. For example, intermediate energy deuterons could be useful in the production of 64 Cu via the nat Zn(d,x)-process, a 3 He-particle beam in the production of 75 Br by the 75 As( 3 He, 3n)-process and an α-particle beam in the production of 38 K and 73 Se via the 35 Cl(α, n) 38 K and 70 Ge(α, n) 73 Se reactions, respectively (for more details cf . [25] ).
Similar to some commonly used positron emitters made available via generator systems, a few novel and potentially useful positron emitters could also be produced through generators. Some of them are: 44 44 Ti reaction is rather low [cf . 61]. All of the above mentioned parent radionuclides can be produced only using intermediate energy cyclotrons.
Novel therapeutic radionuclides

General remarks
The number of potentially interesting therapeutic radionuclides is very large, especially among the lanthanoids [cf . 62]. However, as mentioned above, in internal radionuclide therapy the emphasis has shifted to low-range but highly ionising radiation emitters. They include low-energy β − emitters and α-particle emitters as well as Auger and conversion electron emitters. Among the β − emitters, the radionuclides 47 
Novel low-energy β − emitters
The production of the six low-energy β − emitting radionuclides mentioned above, viz. 47 Sc, 67 Cu, 105 Rh, 161 Tb, 175 Yb and 186 Re, was started using a nuclear reactor, and in the case of 47 Sc, 105 Rh and 161 Tb it is still done at reactors, although following modified routes to achieve higher specific activity. The radionuclide 47 Sc is produced either via the 46 Ca(n, γ ) 47 Ca
Sc process or through the 47 Ti(n, p) 47 Sc reaction. In both cases a highly enriched target is needed. The production via the 47 Ti(n, p) 47 Sc reaction is more economical and the radionuclide has been produced in quantities sufficient for applications, though only using the high flux reactor at BNL [cf . 63, 64] . For the production of 105 175 Yb, expected to give a higher specific activity product, has so far not been developed.
In contrast to 47 Sc, 105 Rh, 161 Tb and 175 Yb, the production of the radionuclides 67 Cu and 186 Re is shifting over to cyclotrons. The quality and quantity of 67 Cu produced by the 67 Zn(n, p) 67 Cu reaction in a nuclear reactor do not meet the specifications required for its use in radioimmunotherapy due to many active and inactive impurities. Its production has been investigated at a small cyclotron (E p = 18 → 12 MeV) through the reaction 70 Zn( p, α) 67 Cu on an enriched target [cf . 66]. The yield is, however, low. More promising is the 68 Zn( p, 2 p) 67 Cu reaction using high-energy protons. This route was applied earlier [cf . 67, 68] . However, since nat Zn was used as target material, the specific activity achieved was rather low for radioimmunotherapeutic applications due to the formation of stable 63, 65 Cu [cf . 64] . Some recent radiochemical measurements [cf . 69] show that a highly enriched 68 Zn target and the energy range E p = 70 → 30 MeV lead to 67 Cu of high quality. A comparison of the 67 Cu yields calculated from the excitation functions of the two production reactions developed at cyclotrons, namely 70 Zn( p, α) 67 Cu and 68 Zn( p, 2 p) 67 Cu, is given in Fig. 2 . Evidently the latter reaction is more suitable, Fig. 2 . Integral yields of 67 Cu in proton-induced production reactions on highly enriched target isotopes 68 Zn and 70 Zn, shown as a function of proton energy (curves are based on the numerical values given in Ref. [117] ).
but it demands an intermediate energy cyclotron. In view of the great therapeutic potential of this radionuclide, considerable efforts are underway in several laboratories to produce it efficiently, mainly via the 68 Zn( p, 2 p) 67 Cu process, i.e. using about 70 MeV protons.
Very recently the reaction 70 Zn(d, αn) 67 Cu on highly enriched 70 Zn has also been investigated over the deuteron energy range of 10 to 20 MeV [70] . The reaction cross sections and the 67 Cu yield are about 50% higher than those for the 70 Zn( p, α) 67 Cu reaction. However, the rare availability of high-intensity 20 MeV deuteron beam and the high cost of the enriched target material may be restrictive factors in the use of this reaction for production purposes.
With regard to the production of 186 Re, the original 185 Re(n, γ ) 186 Re reaction has been dropped due to the resulting low specific activity. The new method of preparation of this radionuclide is the 186 W( p, n) 186 Re reaction, though the 186 W(d, 2n) 186 Re reaction has also been investigated and gives higher yield than the ( p, n) reaction. Most of the studies deal with nuclear reaction cross-section measurements [for a review cf . 71]. Only in three works [72] [73] [74] small scale production has also been reported. A recent critical analysis [71] showed that, for obtaining a high-purity product, an enriched 186 W target is absolutely necessary and the maximum proton energy used should not exceed 18 MeV. The formation of the very long-lived isomer, 186m Re (T 1/2 = 2 × 10 5 a) also needs special consideration in both ( p, n) and (d, 2n) reactions. Presently, efforts are underway in a few laboratories to produce this radionuclide in larger quantities, without which its availability will remain limited.
Research and development work on the production of many other potentially useful β − emitting radionuclides, especially lanthanoids, is also going on. This involves mainly nuclear reaction cross-section measurements using charged particles and development of chemical separations for reactor neutron irradiated targets.
Novel α-emitters
Extensive effort is presently being invested in the development of 225 Ac. On one hand its separation from nuclear waste ( 229 Th) is being optimised and, on the other, the 226 Ra( p, 2n) 225 Ac reaction, making use of the radioactive target material 226 Ra, is being developed [cf . 75] . A third possibility under investigation is its production via irradiation of 232 Th with intermediate energy protons [76, 77] . In the latter case, however, strong chemical effort is involved to separate the desired radionuclide from the fission products.
The α-emitting radionuclide 223 Ra holds great promise for bone cancer therapy [78] 
Novel Auger electron emitters
The production of the radionuclides 67 Ga and 111 In, used previously for SPECT studies and now being considered for Auger electron therapy, is well established (see above). In both cases the ( p, 2n)-reaction on an enriched target is used [cf . 4]. The same is true for 77 Br (T 1/2 = 57.0 h). It was previously regarded as a SPECT nuclide but is now being considered more for Auger therapy. Regarding the potentially interesting Auger electron emitters 131 Cs, 140 Nd, 165 Er, 169 Yb, 193m Pt and 195m Pt, various production methods are under investigation. The radionuclides 165 Er and 169 Yb are produced by the (n, γ )-reaction which again results in low specific activity. Several charged particle induced reactions have been investigated for their production in nocarrier-added form. However, both the radionuclides appear to be unsuitable for open source therapy: the half-life of 165 Er is too short and that of 169 Yb rather long. 169 Yb is being considered for brachytherapy, possibly as a substitute for 192 Ir. But for that purpose the reactor production of 169 Yb appears to be adequate. The radionuclide 131 Cs, on the other hand, is of considerable promise for prostate cancer brachytherapy and it may compete with the wellestablished radionuclide 103 Pd mentioned above. Its effective production through the 131 Xe( p, n) 131 Cs reaction has been demonstrated [cf . 82]. The radionuclide 140 Nd is interesting, not only because of its therapeutic effect but also because of its positron-emitting short-lived daughter nuclide 140 Pr which allows its localisation via PET imaging. Its production is carried out either by the nat Ce( 3 He, xn) 140 Nd process or through the 141 Pr( p, 2n) 140 Nd reaction [cf . 83]. The radionuclides 193m Pt and 195m Pt are pure X-ray and Auger electron emitters, each decay leading to more than Fig. 3 . Experimentally determined and theoretically calculated cross section data for the 192 Os(α, 3n) 193m Pt reaction, shown as a function of the α-particle energy. The model calculations were done using the codes TALYS and STAPRE (taken from Ref. [85] ).
30 secondary electrons. Furthermore, platinum-complexes (like cis-di-chlorodiaminplatinum) have been in use in chemotherapy as potent antitumour agents for a long time. Thus both those radionuclides have great potential in Auger electron therapy. So far the major drawback in their widespread use has been their non-availability with a high specific activity. In a recent study it could be shown that small amounts of 195m Pt could be produced with high specific activity via the 192 Os(α, n) 195m Pt reaction [84] . Using the same target but higher energy α-particles, on the other hand, it was found that 193m Pt of high specific activity could be advantageously produced through the 192 Os(α, 3n) 193m Pt reaction [85] . The excitation function of this reaction is shown in Fig. 3 . It is reproduced very well by nuclear model calculations. Over the optimum energy range E α = 40 → 30 MeV, 193m Pt theoretical yield amounts to about 10 MBq/µA h. Thus this radionuclide can be produced in quantities sufficient for therapeutic applications. This has already been practically demonstrated [86] .
Novel methodologies for production of some established radionuclides
There may be several motivations behind the search for novel methodologies for production of some established radionuclides, e.g., to -increase the yield, radionuclidic purity or specific activity of the desired product, -produce the daughter nuclide directly, if the parent of a generator system is not easily available, -achieve more security in the supply of the radionuclide due to technical constraints regarding irradiation facility. The first motivation has been amply discussed above. The shifts in the production of 64 Cu, 67 Cu, 103 Pd, 186 Re and 193m Pt from reactor to cyclotron serve here as very good examples. Charged-particle induced reactions generally give products of higher specific activity. In some cases, however, even an alternative route does not serve the purpose. For production of 153 Sm, 159 Gd, 169 Er, 192 Ir and several other radionuclides in the group of lanthanoids, for example, extensive charged-particle induced reaction cross-section measurements have been performed at Brussels, Debrecen and Jülich, but no suitable alternative route has been found to replace the (n, γ )-reaction and thus increase the specific activity of the desired product. Only in the case of 153 Sm, the 150 Nd(α, n)-reaction on a highly enriched target bears some promise [cf . 87] to provide a high specific activity product. The cost would, however, be rather high.
In recent years considerable methodological development has followed also on some known generators to improve their performance (e.g. minimisation of breakthrough, improvement in elution yield, concentration of the eluate, etc.). Of particular interest in this respect is the 68 Ge/ 68 Ga system where extensive work has led to a very efficient processing of the 68 Ga-eluate for medical application [cf . 88, 89] . In view of the increasing importance of 68 Ga in labelling molecules for PET studies [cf . [90] [91] [92] [93] this methodology holds great promise.
Under the second motivation, attempts related to "inhouse" direct production of two generator products, namely 62 Cu (T 1/2 = 10 min) and 68 Ga (T 1/2 = 1.13 h), may be mentioned. The 62 Zn/ 62 Cu generator demands frequent production of the parent 62 Zn at a 30 MeV cyclotron because it is rather short-lived (T 1/2 = 9.13 h). It was therefore thought worthwhile to produce 62 Cu directly through the 62 Ni( p, n)-reaction on an enriched target at a small-sized cyclotron [94] or via the 59 Co(α, n)-reaction on a natural target at a medium-sized cyclotron [95] . Those procedures have, however, not found much practical application because of the short half-life of 62 Cu. Regarding the second system, viz. 68 Ge/ 68 Ga generator, though commercially developed, the availability is rather limited. In view of the ever enhancing importance of 68 Ga, the notion is developing to produce this radionuclide directly through the 68 Zn( p, n)-reaction on an enriched target at a small-sized cyclotron or via the 65 Cu(α, n)-reaction on nat Cu at a medium-sized cyclotron (for more discussion cf . [96] ). The prospects for direct production of this radionuclide appear to be favourable, though the effort involved will be much more than in the generator elution.
The most conspicuous and important example under the third motivation is that of 99m Tc. As discussed above, the supply of this commonly used diagnostic radionuclide is rather jeopardized due to increasing uncertainty in the availability of the fission produced 99 Mo for preparing a generator system. An intense search for alternative routes of production of 99 Mo and 99m Tc is therefore imminent. This topic is therefore discussed in more detail. 99 
Alternative routes of production of
Mo and 99m Tc
The suggested routes which are not dependent on a nuclear reactor are given below:
(c) 100 Mo(γ, n) 99 Mo; (d) 100 Mo(n, 2n) 99 Mo;
(e) 100 Mo( p, d + pn) 99 Mo; (f) 100 Mo(d, t + p2n) 99 Mo;
(g) 100 Mo( p, 2n) 99m Tc; (h) 100 Mo(d, 3n) 99m Tc.
It has been suggested [97] that high-energy photons produced at accelerators could be used for production of 99 Mo via photofission of nat U. This would lead to high specific activity 99 Mo, but due to the low photofission cross section of nat U (160 mb), the yield of 99 Mo would be by a factor of about 3.5 × 10 3 lower than that in the neutron induced fission of 235 U. The yield could be increased by developing a high power accelerator, but this has yet to be demonstrated.
The cross section for the formation of 99 Mo in the fission of 232 Th with 22 MeV protons is about 34 mb [98] . Recently, Abbas et al. [99] performed a feasibility study and showed that with 40 MeV protons about 50 GBq of 99 Mo could be produced. This is a potentially useful reaction, provided a high-current accelerator is made available and an effective procedure for the radiochemical separation of 99 Mo is worked out. The expected yields, however, suggest that this procedure could meet the regional demands but not international needs.
The cross section of the 100 Mo(γ, n) 99 Mo reaction is also small (150 mb at the maximum of the peak at 14 MeV) [cf . 100]. A study on the 100 Mo(n, 2n) 99 Mo process [cf . 101] claims that amounts of 99 Mo comparable to those produced through the 98 Mo(n, γ ) 99 Mo reaction in a low flux reactor could be obtained, provided a proper accelerator for 14 MeV neutron production (through the d, t reaction) is developed. The technical difficulties to be overcome are enormous; furthermore, the drawbacks of the 99 Mo produced with large amount of the inactive carrier will remain (see discussion above). More attention is therefore presently focused on production of 99 Mo and 99m Tc using charged-particle induced reactions on 100 Mo. The possibility of production of 99 Mo through the 100 Mo( p, d + pn) 99 Mo reaction was investigated under an IAEA-sponsored project, utilizing highly enriched 100 Mo target [cf . 102]; due to low cross section it was found to be unsuitable. Although GBq amounts of 99 Mo could be produced using long irradiations of thick targets covering the energy range E p = 65 → 10 MeV, the preparation of the generator and, above all, the recovery of the expensive enriched material would pose great technological and handling problems. Furthermore, the product would not be carrier-free. Although subsequent measurements and evaluations [cf . [103] [104] [105] [106] showed slightly higher cross sections, the basic conclusion given in [102] did not change. The 100 Mo(d, t + p2n) 99 Mo reaction has a threshold of about 20 MeV and the cross section is lower than for the proton induced reaction [cf . [107] [108] [109] . Furthermore, in this case also the problem of carrier will remain. It is therefore concluded that this reaction is also not suitable for routine production of 99 Mo, being even less favourable than the 100 Mo
It was also concluded that the direct route of production of 99m Tc via the 100 Mo( p, 2n) 99m Tc reaction at a cyclotron using 22 MeV protons on the target is worth considering for local production and consumption [102] . The corresponding 100 Mo(d, 3n) 99m Tc reaction with 25 MeV deuterons would give a slightly higher yield of 99m Tc [107] [108] [109] , but as deuterons of that energy are rarely available with high intensities, the method is presently not of much interest. As regards the 100 Mo( p, 2n) 99m Tc reaction, recently some more accurate cross section measurements have been done [104] [105] [106] and its practical application was demonstrated first by Guérin et al. [110] and later by Morley et al. [111] . The quality of cyclotron-produced 99m Tc with regard to radiopharmaceutical production was found to be similar to that obtained via the 99 Mo/ 99m Tc generator system. However, the effect of the long-lived impurities ( 97g Tc, 98 Tc, 99g Tc; all with T 1/2 > 10 5 a) on the 99m Tc specific activity has still to be investigated [cf . 112] , as well as the achievable radionuclidic purity as a function of the isotopic composition of the enriched 100 Mo target [cf . 112, 113] . In fact they may both become the deciding factors in the use of the cyclotron-produced 99m Tc. A critical analysis of the 100 Mo( p, 2n) 99m Tc route for the production of 99m Tc at a cyclotron suggests that four basic requirements will have to be fulfilled to make this method effective:
1. Use of highly enriched 100 Mo target, including efficient recycling, 2. Radiochemical separation immediately after irradiation, 3. Daily production schedule, 4. Good logistics.
The target enrichment is crucial. If it is of low enrichment, several radionuclidic impurities ( 95m Tc, 96m Tc, etc.) will occur as it has been shown in recent studies [cf . 112, 113] . The radiochemical separation of 99m Tc from a 100 MoO 3 target could be performed via thermochromatography, as it was done in the case of 94m Tc from a 94 MoO 3 target [114] . Alternatively, a wet chemical method using ion-exchange chromatography could be used [cf . 110, 115] . An important aspect is also the recovery of the enriched target material. Finally, due to its short half-life, the production of 99m Tc will have to be done on a regular (daily) basis, and the supply of various nearby laboratories would need good logistics.
The on-going development work will certainly lead to sufficient quantities of 99m Tc for local or regional use, provided the level of the 99g Tc impurity is comparable to that in the generator produced 99m Tc. However, this author is convinced that it is illusory to expect that the cyclotron production of 99m Tc will solve the world shortage problem. For large scale production and supply to all parts of the world, the utilization of the 235 U(n, f )-process will remain a necessity, though intensive efforts need to be invested to shift the process from high enrichment uranium (HEU) target to low enrichment uranium (LEU) target.
Standardisation of production data
As described above, presently extensive research and development work on various aspects of production of medical radionuclides is going on in many of laboratories. It is therefore imperative that some sort of evaluation of the reported information is done to standardise the data and procedures to be able to assist the user in production of medical radionuclides of acceptable quality.
As regards commonly used reactor radionuclides, extensive neutron-induced reaction cross section data are available in several evaluated nuclear data files (e.g. ENDF/B-VII), thanks to energy-related reactor programmes, and an excellent manual [2] has been prepared concerning other production details of those radionuclides.
For accelerator-based radionuclides, whereas vast information is available, particularly on targetry and chemical separation procedures, no authentic standardisation work has been reported. The main reason is that each laboratory uses a methodology suitable to its own cyclotron and radiochemistry facility. As regards nuclear data for production, however, the situation is better and is discussed below.
All charged-particle induced reaction cross section data are promptly compiled in the EXFOR file coordinated by the IAEA. For potentially interesting production reactions, generally a large number of measurements are available in the literature. It appeared therefore incumbent to devote some effort to the evaluation of those data. The IAEA embarked on this mission about 15 years ago and organised two successive co-ordinated research programmes (CRPs) in which about a dozen laboratories participated, under guidance of the Research Centre Jülich. Since no evaluation methodology existed for charged-particle induced reactions, the initial work was rather empirical. However, in later years strong application of nuclear models could be built in. The evaluated and recommended data for the major diagnostic radionuclides are now available in [116] and those for the therapeutic radionuclides in [117] . They should allow a proper selection of the projectile energy range in a target to ensure high radionuclidic purity of the desired product. In addition, the exact yields of the desired radionuclide and the accompanying radioactive impurities can be accurately calculated. A few groups are now also individually engaged in this type of work [cf . 21, 118] .
Further work on the validation of evaluated data as well as on the evaluation of data for other emerging radionuclides is necessary.
Future directions and perspectives
Radioactivity has revolutionized medicine. The radionuclide production technology is well developed and several suitable radiopharmaceuticals are now widely available for patient care, both with respect to diagnosis and radiotherapy. The future prospects of the tracer technology look bright. However, innovative notions and approaches will need to be followed to keep pace with other medical imaging diagnostic and therapeutic techniques. The emerging problems will demand enhanced attention in the following directions.
Patient care programme
With regard to the apprehension about the secure supply of the most commonly used diagnostic radionuclide 99m Tc, presently produced by fission of highly enriched 235 U, it is likely that the industry would modify the industrial production process to be able to cope with the use of low-enriched 235 U (thereby reducing the danger of nuclear weapons' proliferation). The dependence on nuclear reactors will, however, remain. If at the same time some countries in the OECD-area may decide to utilize a few modern research reactors for production of fission 99 Mo, the situation may improve. At least one initiative to make use of the München reactor for this purpose appears promising. Furthermore, if a few new powerful research reactors could be constructed in countries with fast developing economies and technologies, e.g. China, the problem could be solved. On the other hand, if no progress is made in the above mentioned three directions, several scenarios may emerge, e.g.
1.
Cyclotron production of 99m Tc. As mentioned above, the question of short-and long-lived impurities needs urgently to be solved. Furthermore, this would offer only a regional solution in technologically advanced countries. It will be beyond the reach of developing countries. 2. Production of 99 Mo by fission of low-enriched 235 U for regional (not global) supply. Countries like Argentina, South Africa, Russia, India, Pakistan, Ukraine, etc. could do so. Some of them are already developing the methodology and producing appreciable quantities of fission 99 Mo. 3. Enhanced production of 99 Mo through the (n, γ ) reaction and intensified efforts to make use of the gel generator, as it is done today in a few developing countries. 4. Development of future technologies, e.g. production of 99 Mo by fission of nat U, using an accelerator based intense photon or spallation neutron source. The spallation neutron source would be very suitable also for the production of several therapeutic radionuclides via the (n, p) Thus considerable efforts may be called upon to ensure the smooth running of patient care programmes.
Research orientations
For research studies, the demand for longer lived positronemitting radionuclides, which have passed the stage of laboratory scale production and clinical evaluation, e.g. 64 Cu, 86 Y, 89 Zr and 124 I, will certainly increase. The same may be true for other potentially useful positron emitters, such as 55 Co, 71 As, 72 As and 73 Se. If the demands for those radionuclides increase further, it may become incumbent to intensively search for intermediate energy production routes leading to higher yields and purity.
With regard to quantification of SPECT-radiopharmaceuticals, an analogue approach is applied which involves the use of a positron-emitting nuclide of the chemical element of the SPECT radionuclide. Thus for quantification of several 99m Tc-radiopharmaceuticals, labelling of the compound was carried out using the positron emitting radionuclide 94m Tc (T 1/2 = 52 min) followed by a PET measurement. If the shortage of 99m Tc becomes acute, it is likely that 123 I-radiopharmaceuticals will play a more important role in the future than today. For quantification of those radiopharmaceuticals, resort may have to be made to a short-lived positron emitting radioiodine, e.g. 120 I (T 1/2 = 1.3 h). An important application of positron emitters is in quantification of radiation dose in internal radionuclide therapy.
Combining a positron-emitting isotope of an element together with a therapeutic radioisotope of the same element, it is possible to measure the uptake kinetics by PET imaging, thereby allowing an accurate dosimetric calculation related to therapy. The principle was first applied in the case of internal therapy with 90 Regarding internal radiotherapy, presently a shift is taking place from the use of β − particle emitters to Auger electron and α-particle emitters which induce more cellular effects. Several radionuclides are at the development stage (see above, Sect. 3.2), but once the principles have been established, the demands for those radionuclides will increase. Many of them are low-lying, highly converted, high spin states and are difficult to produce. Versatile nuclear routes will have to be harnessed, involving also intermediate energy reactions or even heavy-ion induced reactions. In short, elegant interdisciplinary approaches will be needed to obtain the desired radionuclides in high yield and purity.
A new perspective of medical radionuclides is emerging through extremely significant developments that are currently taking place in organ imaging. The dynamic and quantitative nature of PET (and recently to some extent also SPECT) is being coupled with X-ray tomography (CT) and magnetic resonance imaging (MRI) to provide a highly powerful combination of systems for organ imaging. The radionuclides of potential interest for the latter combination are considered below.
In MRI the elements Mn and Gd are often used as contrast agents. If a positron-emitting radionuclide is introduced in the system, the high-resolution of MRI and the quantitative nature of PET could lead to very high quality imaging. In the case of manganese the positron emitting radionuclide 51 Mn (T 1/2 = 46.2 min) has been suggested [cf . 122, 123] . Regarding gadolinium, no positron-emitting radionuclide is available. However, it has been demonstrated that this element could be converted to a so-called "intelligent (responsive) agent" [cf . 124] by chemically binding it with a metal like Cu through pyridine [125] ; This considerably increases the contrast. Now if copper could be a positron emitter, e.g. 64 Cu, PET and MRI could be advantageously combined. A newer concept involves the conversion of a transition metal complex from the dia-to paramagnetic state (spin crossover) which can be used as a contrast agent [cf . [124] [125] [126] [127] . The metals of interest are Fe and Ni and the potentially useful positron emitting radionuclides could be 52 Fe (T 1/2 = 8.3 h) and 57 Ni (T 1/2 = 36.0 h), respectively. In view of the increasing interest in multimode imaging, the need for further development of suitable novel positron emitters will certainly increase.
Another long-term perspective of radionuclide technology could involve an intensive combination of radioactivity and nanotechnology. In recent years, the latter technology has made tremendous progress and its applications are now in many fields, including nuclear energy technology [cf . 128] . Also in medical radionuclide research, nanotechnology has found some connection, e.g. in production of a radionuclide for nanobioscience application [cf . 129] , in construction of a generator column using a nanomaterial [cf . 130] and in retention of the recoiling daughter in an in vivo generator used in alpha radionuclide therapy [cf . 131] . Similarly, nanotargeted materials are finding increasing applications in tumour imaging and tumour therapy (for recent reviews cf . [132, 133] ). The types of needed radionuclides are generally the same as in conventional diagnosis and therapy described above.
Concluding remarks
It should be mentioned that also in the future the radionuclide production technology will strongly depend on research reactors as well as small and medium-sized cyclotrons with energies up to about 30 MeV. For production of many emerging radionuclides, however, intermediateenergy, high-intensity accelerators with proton energies up to about 100 MeV will be required. Furthermore, there will be a need for higher energy facilities to accelerate also deuterons, 3 He and 4 He particles in order to extend the range of production and to improve the radionuclidic purity. In particular the 4 He particle beam may be quite advantageous for producing many of the therapeutic radionuclides. Needless to say, that highly qualified personnel with expertise in interdisciplinary areas of physics, chemistry, biology, medicine and engineering will always be needed to maintain, nurture and further develop this sophisticated technology for the benefit of human beings.
